Growth Hormone Secretagogues: A Complete Guide

Growth hormone secretagogues (GHS) are compounds that stimulate the pituitary gland to release more growth hormone (GH). Unlike exogenous GH injections (such as pharmaceutical somatropin), secretagogues work with your body's natural feedback mechanisms rather than bypassing them.

This distinction is important. When you inject synthetic GH directly, you're adding GH from outside the body, which can suppress natural production over time. Secretagogues, by contrast, encourage the pituitary to produce and release more of its own GH, generally preserving the body's natural pulsatile release pattern.

There are three main categories of GH secretagogues:

• •GHRH analogues (Growth Hormone Releasing Hormone) — Mimic the hypothalamic hormone that signals GH release. Examples: CJC-1295, Sermorelin, Tesamorelin.
• •GHRPs (Growth Hormone Releasing Peptides) — Act on the ghrelin receptor to amplify GH pulses. Examples: Ipamorelin, GHRP-6, GHRP-2, Hexarelin.
• •Non-peptide secretagogues — Oral compounds that stimulate GH release. Example: MK-677 (Ibutamoren), which is technically not a peptide but is often discussed alongside them.

GHRH analogues mimic the body's natural Growth Hormone Releasing Hormone, which is produced by the hypothalamus and travels to the pituitary gland to trigger GH secretion.

CJC-1295 (with DAC) The most widely discussed GHRH analogue. The Drug Affinity Complex (DAC) modification extends its half-life to 6-8 days, allowing less frequent dosing. CJC-1295 with DAC produces a sustained, elevated baseline of GH rather than sharp pulses — which can be advantageous for consistent tissue repair and recovery but may not perfectly replicate natural GH dynamics.

CJC-1295 (without DAC) / Mod GRF 1-29 A shorter-acting version with a half-life of approximately 30 minutes. This creates more physiological GH pulses — a sharp rise followed by a return to baseline. Many researchers prefer this version for its more natural release pattern, though it requires more frequent administration.

Sermorelin One of the earliest GHRH analogues studied clinically. Sermorelin has a shorter half-life than CJC-1295 and was previously available as a pharmaceutical product (Geref) before being discontinued. It remains popular in the research peptide market and anti-ageing clinics.

Tesamorelin A GHRH analogue approved by the FDA for reducing visceral adipose tissue in HIV-associated lipodystrophy (brand name: Egrifta). It has clinical trial data supporting its effects on body composition and may have neuroprotective properties based on preliminary research.

Growth Hormone Releasing Peptides work through a different pathway — they bind to the ghrelin (GHS) receptor in the pituitary and hypothalamus, amplifying GH release. When combined with GHRH analogues, GHRPs create a synergistic effect that produces significantly higher GH output than either class alone.

Ipamorelin Considered the most selective GHRP, meaning it stimulates GH release with minimal impact on cortisol, prolactin, or appetite. This selectivity makes it a popular choice for researchers seeking GH elevation without unwanted hormonal side effects. Typical research doses range from 100-300mcg.

GHRP-6 A potent GH secretagogue that also significantly increases appetite through ghrelin receptor activation. The hunger effect can be pronounced — some users report intense appetite within 20-30 minutes of administration. This makes GHRP-6 useful for research into appetite stimulation but less ideal for those seeking GH benefits without caloric drive.

GHRP-2 More potent than GHRP-6 for GH release but with moderate effects on appetite, cortisol, and prolactin. It sits between Ipamorelin (most selective) and GHRP-6 (least selective) in terms of side effect profile.

Hexarelin The most potent GHRP for raw GH release, but also the least selective. It can significantly elevate cortisol and prolactin, and its GH-stimulating effect tends to desensitise more quickly with repeated use than other GHRPs. Generally reserved for short-term research protocols.

The most well-established principle in GH secretagogue research is the synergistic effect of combining a GHRH analogue with a GHRP. This combination produces GH release significantly greater than the sum of either compound alone.

Why the synergy works: GHRH and GHRPs work through complementary pathways. GHRH sets the "amplitude" of the GH pulse (how high it goes), while GHRPs set the "frequency" and "initiation" of the pulse. Together, they create a larger, more robust GH release than either pathway can achieve independently.

The most popular research stack: CJC-1295 (no DAC) + Ipamorelin, often called the "CJC/Ipa" combination. This pairing is favoured because: - Ipamorelin's selectivity minimises side effects - Mod GRF 1-29's short half-life creates physiological GH pulses - The combination produces significant GH elevation with a clean side effect profile - Both peptides are well-characterised in research literature

Timing considerations: For maximum GH release, research protocols typically suggest administration during natural GH troughs — typically upon waking, post-exercise, or before sleep. Administering during a natural GH peak wastes the secretagogue's potential because the pituitary is already actively releasing GH.

What about MK-677? While MK-677 (Ibutamoren) is often grouped with peptide secretagogues, it's actually a non-peptide oral GHS receptor agonist. Its 24-hour half-life provides sustained GH elevation but can increase appetite, water retention, and insulin resistance with prolonged use. It's a convenient option (oral dosing) but lacks the precision of injectable peptide combinations.